Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27515794 | 0.98 | NOS1 (0.51) | NOS1DHFR | |
| SCHEMBL29612407 | 0.98 | NOS1 (0.51) | NOS1DHFR | |
| Bromide SCHEMBL30761717 | 0.87 | NOS1 (0.52) | NOS1DHFR | |
| Bromide SCHEMBL29695506 | 0.87 | NOS1 (0.52) | NOS1DHFR | |
| Bromide SCHEMBL2553255 | 0.87 | NOS1 (0.52) | NOS1DHFR | |
| Bromide SCHEMBL29515501 | 0.87 | NOS1 (0.52) | NOS1DHFR | |
| Bromide SCHEMBL1116048 | 0.87 | NOS1 (0.52) | NOS1DHFR | |
| SCHEMBL31143797 | 0.85 | NOS1 (0.54) | NOS1DHFR | |
| SCHEMBL64146 | 0.85 | NOS1 (0.54) | NOS1DHFR | |
| SCHEMBL30435493 | 0.85 | NOS1 (0.54) | NOS1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171376-A1 | Antiarthritic agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6559149-B1 | Lesser side effects without compromise in their efficacy | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-06 | — | — | US | disclosed |
| EP-0632038-A1 | METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171376-A1 | Antiarthritic agents | BCOR, RCOR1, IL4 | NOS1 199/4885DHFR 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.